A systematic review of risk factors for nonadherence and non-persistence to anti-VEGF treatment in wet AMD patients stated that non-persistence appears early, with almost 50% of patients discontinuing treatment within 24 months [41]. The gene discussed is VEGFA; the disease is wet macular degeneration.